Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis

Molino, Annamaria; Pelosi, Giuseppe; Turazza, Monica; Sperotto, L.; Bonetti, Andrea; Nortilli, Rolando; Fattovich, G; Alaimo, C.; Piubello, Quirino; Pavanel, Flavia; Micciolo, Rocco; Cetto, Gian Luigi

doi:10.1023/a:1005747711084

Cited by 61 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are consistent with two previous studies (16,17), but in contrast to the work of Ikeda et al (13), who found that positivity of axillary lymph node metastases and lymphatic vessel invasion were significantly higher (P Ͻ 0.05) in the CK19 PCR-positive patients than the negative patients.…”

Section: Discussionsupporting

confidence: 93%

Detection of Micrometastatic Disease and Monitoring of Perioperative Tumor Cell Dissemination in Primary Operable Breast Cancer Patients Using Real-Time Quantitative Reverse Transcription-PCR

Ismail

Wynendaele

Aerts

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: We previously found a statistically significant number of cytokeratin 19 (CK19)؉ cells in peripheral blood (PB) of stage IV breast cancer (BC) patients compared with those of healthy volunteers, using a quantitative real-time reverse transcription-PCR. We aimed to apply the technique on bone marrow (BM) of primary operable BC patients. Pre-and postoperative PB samples of these patients were further analyzed to investigate possible shedding of CK19؉ cells during the operation.Experimental Design: In 54 primary operable BC patients, we analyzed 50 BM samples taken preoperatively and 297 PB samples. PB samples were collected before surgery; immediately after surgery; on the first, second, and fifth day postoperatively; and one month postoperatively.Results: In BM of controls and BC patients, we detected a median of 28 and 568 CK19؉ cells/5 ؋ 10 6 leukocytes, respectively (P < 0.001). In preoperative blood (B-1) samples, we measured a median of 109 CK19؉ cells. Using the upper limit of 95% confidence interval of controls as cutoff, 74% and 52% of BM and (B-1), respectively were considered CK19؉. There was no significant correlation between CK19؉ cells in BM and (B-1) and classical prognostic factors. We found no significant difference between blood samples at different time points with respect to the average CK19؉ cells. Conclusions:In primary BC patients, we detected high numbers of CK19؉ cells in BM and PB (B-1) samples compared with controls. However, no significant correlation between the presence of CK19؉ cells in BM and PB and classical prognostic factors was found. We detected no statistically significant influence of surgical manipulation on CK19؉ cells.

show abstract

Section: Discussionsupporting

confidence: 93%

Detection of Micrometastatic Disease and Monitoring of Perioperative Tumor Cell Dissemination in Primary Operable Breast Cancer Patients Using Real-Time Quantitative Reverse Transcription-PCR

Ismail

Wynendaele

Aerts

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…To our knowledge, the antibodies used in their study have not been tested in other clinical trials, and the specificity of these can be questioned. Furthermore, their BM analyses at diagnosis did not correlate to clinical outcome (24). In other studies, repeated BM examinations have mostly been performed in high-risk and metastatic breast cancer patients receiving high dose chemotherapy and/or immunotherapy (10,25,26).…”

Section: Discussionmentioning

confidence: 97%

Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1

Wiedswang

Borgen²,

Kåresen

et al. 2004

Clinical Cancer Research

176

113

View full text Add to dashboard Cite

Purpose: The aim of the study was to explore the value of analyzing bone marrow (BM) for the presence of isolated tumor cell(s) (ITCs) in disease-free breast cancer patients 3 years after diagnosis.Experimental Design: ITCs in BM at operation was found to be an independent prognostic factor in 817 breast cancer patients. Among these, 356 disease-free patients were analyzed with a second BM after 3 years follow-up (median 40 months, SD 3 months, range 29 -52). ITC was detected by immunocytochemistry with anticytokeratine antibodies (AE1/AE3).Results: The population consisted of 70% T 1 and 72% node-negative patients. ITC in BM was detected in 15%. At a median of 25 months since the second BM aspiration (66 months since diagnosis), 32 patients had developed relapse, 12 local and 20 systemic. Of the patients with ITC in BM, 21% relapsed compared with 7% of the ITC-negative patients (P < 0.001). Ten patients died of breast cancer. Survival analyses showed that ITC in BM predicted reduced distant disease-free survival (DDFS) and breast cancer specific survival (BCSS; P < 0.001, log-rank test). Uni-and multivariate analyses of the prognostic value of N, T, estrogen receptor/progesterone receptor, and BM status, histological grade, vascular invasion, p53-, c-erb-B2-, and cathepsin D expression were performed. BM status was the only independent prognostic factor for both DDFS and BCSS, whereas c-erbB-2 and N status were independent for BCSS and vascular invasion and T status for DDFS.Conclusions: ITC in BM 3 years after diagnosis in disease-free breast cancer patients is an independent prognostic factor. Detection of residual disease by BM analysis at follow-up may unravel insufficient adjuvant treatment. The clinical implications should be further explored.

show abstract

“…The search for epithelial cells by immunocytochemical (IC) techniques in the bone marrow (BM) has been already studied by several authors as a potential prognostic factor for patients [2][3][4] with breast cancer (BC) and more recently as a potential marker of response to adjuvant chemotherapy [5]. In fact, a previous meta-analysis has been conducted in 1998 by Funke and Schraut [6] in order to summarize the evidence regarding the prognostic utility of this methodology.…”

Section: Introductionmentioning

confidence: 99%

Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis

Weinschenker

Soares

Clark³

et al. 2004

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis

Abstract: In our series, bone marrow positivity did not correlate with prognostic parameters or prognosis. Of interest is the relative excess of positivity when the bone marrow was obtained during surgery.

Cited by 61 publications

References 16 publications

Detection of Micrometastatic Disease and Monitoring of Perioperative Tumor Cell Dissemination in Primary Operable Breast Cancer Patients Using Real-Time Quantitative Reverse Transcription-PCR

Detection of Micrometastatic Disease and Monitoring of Perioperative Tumor Cell Dissemination in Primary Operable Breast Cancer Patients Using Real-Time Quantitative Reverse Transcription-PCR

Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1

Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis

Contact Info

Product

Resources

About